Jun 10, 2020
Eddie Sullivan, President, CEO, Co-Founder, SAb Biotherapeutics talks about their innovative technology to generate targeted highly potent immunotherapies on a large scale. SAb is producing fully human polyclonal antibodies targeted to COVID-19 without the need for convalescent plasma blood donations by using genetically engineered cattle which produce the fully human antibodies.
@SABBantibody
#COVID19 #immunotherapies #antibodies